| 2009 | Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2007 | Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG) | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2010 | Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2010 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2013 | Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2014 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2015 | Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2012 | Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2019 | Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors | Cancer Chemotherapy and Pharmacology |
| 2017 | Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2018 | Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2011 | Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
| CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2020 | Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2012 | The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
